Anagliptin clinical trials
Also written SK-0403.
How each study uses anagliptin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the anagliptin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2010 (2)
| Year | Studies |
|---|---|
| 2010 | 2 |
| 2011 | 2 |
| 2015 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 1
JW Pharmaceutical (3) · Kowa Research Institute, Inc. (2) · Institute for Clinical Effectiveness, Japan (1) · Sanwa Kagaku Kenkyusho Co., Ltd. (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of DPP-4 inhibitors source
- One of Protease Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test anagliptin.
- Mar 2027Glycemic Variability of Combination Therapies in T2DMPhase 4 · JW Pharmaceutical
Studies
Open first, then newest update. How each study uses anagliptin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Glycemic Variability of Combination Therapies in T2DMRecruitingPhase 4JW PharmaceuticalNCT07442006Written as Anagliptin
- Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes TrialCompletedPhase 4Institute for Clinical Effectiveness, JapanNCT02330406Written as Anagliptin
- Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin AloneCompletedPhase 3JW PharmaceuticalNCT01529541Written as Anagliptin
- A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus PatientsCompletedPhase 3JW PharmaceuticalNCT01529528Written as Anagliptin
- A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin TherapyCompletedPhase 2Kowa Research Institute, Inc.NCT01169090Written as SK-0403
- A Multicenter, Open Label, Single Dose Study to Evaluate the Effect of Renal Insufficiency on the Pharmacokinetics of SK 0403CompletedPhase 1Kowa Research Institute, Inc.NCT01131091Written as SK-0403
- Phase II Dose-Finding Study of SK-0403 With Type 2 Diabetes MellitusCompletedPhase 2Sanwa Kagaku Kenkyusho Co., Ltd.NCT00532506Written as SK-0403
Codes
What other systems call anagliptin · ClinicalTrials.gg INT006341
- MeSH (NLM) C583175anagliptinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) K726J96838ANAGLIPTINConfirmed FDA, NLM, Wikidata
- Wikidata Q15269682anagliptinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C96202AnagliptinOne source FDA
- DrugBank DB12417One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C583175 | anagliptin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | K726J96838 | ANAGLIPTIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q15269682 | anagliptin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C96202 | Anagliptin | One source FDA |
| DrugBank | DB12417 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.